Similarly, the price-to-free-cash-flow ratio is significantly higher at 67.16x, compared with the peer group average of 31.96x.

FORBES: Momentum Players Have Lots To Like About Haemonetics

However, the price-to-free-cash-flow ratio looks attractive at 19.29x, a roughly 13.8% discount to the peer group average of 22.37x.

FORBES: ResMed Breathes Easy In Rarefied Air